SARS-CoV-2 variants and vulnerability at the global level

Vivek P. Chavda1 | Aayushi B. Patel2 | Darsh D. Vaghasiya2

1Department of Pharmaceutics and Pharmaceutical Technology, L.M. College of Pharmacy, Ahmedabad, Gujarat, India
2Pharmacy Section, L.M. College of Pharmacy, Ahmedabad, Gujarat, India

Abstract
Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity established with the existing COVID-19 vaccination. These variants are more transmissible, induce relatively extreme illness, have evasive immunological features, decrease neutralization using antibodies from vaccinated persons, and are more susceptible to re-infection. The Centers for Disease Control and Prevention (CDC) has categorized SARS-CoV-2 mutations as variants of interest (VOI), variants of concern (VOC), and variants of high consequence (VOHC). At the moment, four VOC and many variants of interest have been defined and require constant observation. This review article summarizes various variants of SARS-CoV-2 surfaced with special emphasis on VOCs that are spreading across the world, as well as several viral mutational impacts and how these modifications alter the properties of the virus.

KEYWORDS
Delta plus variant, Delta variant, mutation, Omicron variant, SARS-CoV-2, vaccination, viral variant

1 | INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in a great rise in morbidity and mortality all across the globe. Over 4000 SARS-CoV-2 mutations have been detected as the worldwide SARS-CoV-2 outbreak proceeds. Attempts are being made to detect viral mutations and different viral strains. The ultimate goal of the current research toward COVID-19 is to discover new viral mutations fast and determine their potential consequences. A mutation occurs when the pattern of the gene is altered. The order of these nucleotides in RNA or DNA determines the amino-acid sequence. Proteins are constructed from amino acids and are species-specific.

A mutation in a viral genome can alter the encoded amino acid sequences, which can cause the virus to replicate. Mutations are classified into two types: deletion and substitution. Substitution can originally be referred to as a proofreading process, but deletions cannot. The genome present in SARS-CoV-2 consists of 14 open reading frames (ORFs) of which two-thirds are responsible for encoding 16 nonstructural proteins (NSP 1–16) necessary to make up the replicase complex. The remaining one-third ORFs are involved in the encoding of four proteins that are S (Spike), N (Nucleocapsid), M (Membrane), E (Envelope), and nine accessory protein-ORFs. S (Spike) proteins are required for entry of COVID-19 virus into host cells. NSP 14 performs proofreading for the SARS-CoV-2 virus. Mutations are always to be anticipated, despite the fact that not all mutations are purposeful or advantageous to the virus. Viral variants are the outcome of mutations that occur throughout viral replication. A mutation is an alteration in a genome of a virus pattern that differs from the typical pattern, including a replacement, removal, or inclusion. The SARS-CoV-2 virus is no exception, and multiple variants of the same have been reported all over the globe since its inception. Considering a growing frequency of instances identified viral variants with mutation sites in the viral spike protein’s receptor-binding domain (RBD) region have garnered widespread interest, the RBD is the primary focus of neutralizing antibodies generated after infection of SARS-CoV-2. Some abnormalities in the S protein, like those reported in the N-terminal
domain (NTD), may also affect neutralizing antibody capacity. A reconstituted SARS-CoV-2 (virus or genetic mutant) may have additional mutations that separate it from the basic pattern or common viral variants widely circulated in humans. The proliferation of mutations poses a significant barrier for vaccination-based protection and management of the SARS-CoV-2 outbreak. Existing SARS-CoV-2 vaccines have been approved for immediate application. Those vaccines that are in clinical trials have also demonstrated substantial benefits in terms of offering effective coverage toward novel viral variants. This review encompasses the impact of identified variants on neutralizing antibodies and the preventive effect of various vaccines. We have also proposed ways for using present vaccines toward variants as well as generating upcoming vaccines.

2 | VARIANTS OF THE SARS-COV-2

SARS-CoV-2 variants can have a variety of features. Testing results may be affected if a patient sample contains SARS-CoV-2 viral mutations. Multiple factors, including the variant sequence, examination system, and the incidence of change in the population, are used to analyze the influence of mutations on test performance. Typically, transcription or translation error in the viral genome is the main reason for mutation. It has been shown that RNA viruses undergo mutation at higher rates than DNA viruses with mutation rates from $10^{-6}$ to $10^{-4}$ substitutions per nucleotide, per round of copying. The high rate of mutation is correlated with an increase in evolvability and enhanced virulence, which is a beneficial survival trait for viruses. Mutation in viruses causes both geno- and phenotypic changes as seen in an influenza A virus. The main reason for mutation in the influenza A virus is the re-assembly of viral genomes from different strains. The mutation causes the change in patterns of influenza A subtype H3N2 which is responsible for antigenic evolution in humans. Influenza viruses are ever-shifting in two ways, antigenic drift and antigenic shift. The first is responsible for causing small mutation in genes of the virus which leads to changes in HA (hemagglutinin) and NA (neuraminidase), which are surface proteins and later creates a substantial shift in influenza A viral surface protein produces new HA and/or NA surface proteins, that are relevant to human infection. In conjunction with the SARS-CoV-2 interagency committee, the CDC defined three categories of SARS-CoV-2 variants: variants of interest (VOI), variants of concern (VOC), and variants of high consequence (VOHC). These variants are continually evolving as a result of the number of additional alterations (Figure 1).

2.1 | VOI

It is a variation associated with altered receptor binding, reduced neutralization by antibodies generated in response to past infection or immunization, reduced therapeutic efficacy, possible diagnostic effect, or an anticipated rise in infectivity or growth of the disease. This variation has a nonidentical sequence of receptor binding. Antibodies that are created against additional infection or vaccination can reduce the neutralization. The efficacy of treatment gets reduces which leads to the possible impact of diagnosis or an anticipated increase in infectiousness, or intensity of the disease. Table 1 summarizes VOI that are being monitored to date. A mutation, known as D614G, is responsible for one specific viral activity. It is reflected in the reality that viruses with this mutation behave differently from wild-type viruses. The D614G mutation is present in nearly all SARS-CoV-2 strains circulating globally today and is highly associated with clinical severity and transmissibility. It is likely that the D614G mutation provides a fitness advantage to the virus, allowing it to spread more efficiently in the population. This mutation is the key to understanding how SARS-CoV-2 has evolved over time and how it has become so successful at infecting humans.
alteration have a higher transmission rate than viruses without this variation.  In the starting phase of the pandemic, this mutation was one of the first documented mutations in the United States, after having initially circulated in Europe.  "The phylogenetic assignment of named global outbreak lineage (PANGOLIN)," also known as Pango lineage terminology, was used to designate SARS-CoV-2 variants. The phylogeny of SARS-CoV-2 is divided into two primary lineages, A and B, as per nomenclature. The most typical lineage of variations is debated.  

### 2.2 | VOC

A variation characterized by increased amplitude, a substantial decrease in treatment potency or vaccine performance due to neutralization with antibodies produced following previous sickness or inoculation, or diagnostic identification errors (Figure 2). The transmission rate is excessive in this variant type of SARS-CoV-2 (Tables 2 and 3). A high rate of transmission leads to more acute disease. There is a possible decrease in neutralization by antibodies produced from earlier illness or immunization. The efficacy of medicines or vaccinations is decreased, or diagnostic recognition fails. Table 4 summarizes all the potential mutations of SARS-CoV-2 variants and their impact.

#### 2.2.1 | Alpha variant

WHO has reported that instances of Alpha variants have been diagnosed in around 170 countries and in various territories across the globe. The United Kingdom, Japan, Alaska, the United States of America, and Turkey have faced the severe effect of this alpha variant. More than 10,000 cases of Alpha variant are reported in these countries. Other than these countries, Canada, Mexico, Brazil have also reported more than 8000 confirmed cases and in India, Peru, Russia, China there were around a thousand cases reported of Alpha variants.

This is the first VOC reported in the WHO study on variant classification. This strain clade 201/S01Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized Alpha variant by various scientific names. In the United Kingdom, the very first case of the SARS-CoV-2 Alpha variant was detected in September 2020.

Furthermore, the Alpha variant is related to a greater death rate in patients in comparison with other variants. The alteration in the S protein of the virus is the main reason behind its mutation. This new variant also carries NTD and RBD mutations, which play a vital part in the binding of a virus with host cells via the angiotensin-converting enzyme 2 (ACE2) receptor. S1 subunit of viral spike protein, which is made up of the NTD and the RBD, is essential for defining tissue tropism and host ranges.

The N501Y mutation in the RBD of the spike protein, and a few additional mutations, identify the Alpha variant. Among these, there are two deletion mutations in the NTD of the S protein, HV69-70del and Y144del (also known as Y145del due to the presence of tyrosine at both positions). SARS-CoV-2 variants with membrane (M) protein alterations, such as I82T and V70L, have recently been identified as a potential cause of concern. The Alpha variant was revealed to be the result of the consecutive acquisitions of mutations in M Protein: V70L in November 2020 and the unique S Protein: D178H mutation in early February 2021. Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson and Johnson, and Novavax have all proven that their vaccines, based on various designs, can all be effective against this variation. In Phase 3 clinical trial done in the United Kingdom for the Novavax vaccine, for example, showed an efficacy of 89.3% against an Alpha variant (NCT04611802).

SARS-CoV-2 mutations are frequent; the COVID-19 Genomics UK (COG-UK) Consortium reports that around 4000 mutations have been identified in its spike protein alone. There are 23 mutations in VOC-202012/01: 14 nonsynonymous mutations, 3 deletions, and 6 identical mutations. Furthermore, the Alpha variant is related to a greater death rate in patients in comparison with other variants. The alteration in the S protein of the virus is the main reason behind its mutation. Two vaccinations with either BNT162b2 or ChAdOx1 nCoV-19 demonstrated good protection against Alpha variant and reduces the viral transmission. Another study estimated the efficacy of the Pfizer vaccine of roughly 90%.

#### 2.2.2 | Beta variant

Numerous official designations are assigned to the beta variant, including strain clade 20H/S01.V2 and Pango lineage B.1.351. The first incidence of the SARS-CoV-2 beta strain was identified in the United Kingdom in May 2020, and it was mostly discovered in South Africa. The mutation caused an increase in transmissibility and also the neutralizing capacity of the virus. There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246L, A701V, that have so far raised little concern. Aside from the spike area, it also has K1655N, a deletion of SGF 3675-3677, P71L, and T205I.
According to the weekly update released by WHO on June 22, 2021, the cases of beta variants are reported in almost 119 countries.58 Due to the mutation, there is a reduction in the susceptibility of a virus toward the combination of some monoclonal antibody treatment, like a combination of bamlanivimab and estesevimab.47 In the RBD of spike protein, notable mutations include N501Y, K417N, and E484K, which can increase the protein’s affinity for the human ACE2 receptor.59 The E484K mutation may allow an individual to evade the immune system’s response.60 According to an in vitro test, all existing vaccines generate antibodies with decreased neutralizing activity against beta variants.58,61 Overall vaccine efficacy for COVID-19 of any severity was 33.5% up to 14 days after the first vaccine dose.56 Safety and immunogenicity study of a SARS-CoV-2 variant vaccine (mRNA-1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144).
2.2.3 | Gamma variant

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID-19. This variant contains 17 amino acid substitutions and among them, 10 are in its spike protein.60 This variant was found in Japan. It was later transmitted in Brazil.62 This variant comprises two subvariants 28-AM-1 and 28-AM-2 that both carry mutation K417T, E484K, and N501Y. Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).63 The immunological escape mutation (E484K) is present in this variant.64 SARS-CoV-2 variants gamma contains 10 defining mutations in its spike protein, including N501Y and E484K, in addition to eight other mutations (four of which are synonymous genetic variants) in its ORFs (ORF1a and ORF1b), one of which is a deletion.65 The severity of the disease toward death was reduced in this variant.66 After vaccination with Moderna or Pfizer, the gamma variant has been demonstrated to be relatively resistant to neutralization by convalescent plasma and vaccine sera.66 The severity of the disease toward death was minor (3.8–4.8-fold).67

CoronaVac, an inactivated vaccine has been demonstrated to be 50% effective in preventing sickness 14 days after the first dose in a two-dose regimen. Over 1000 cases of this variant are diagnosed in Brazil and the United States of America, and less than 100 instances are detected in India, Canada, Australia, and Mexico.60 In February 2021, more COVID-19 individuals with no comorbidities were admitted to the ICU. Gamma was discovered to be prevalent in adolescent ICU patients in February 2021.64 Reinfection by gamma is widespread and may play a large role in epidemics where this variant is prevalent in the population.69 Although the clinical significance and transmissibility of reinfections were not investigated, the projected reinfection rates imply that the gamma variant may cause a greater infection risk than earlier non-gamma versions.64 As the majority of blood donors had asymptomatic or oligosymptomatic illnesses, the found protection against reinfection does not generalize to cohorts of exclusively hospitalized or symptomatic people.64,69,70

2.2.4 | Epsilon variant

These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA). In the beginning, they were designated as CA VUI1 but afterward WHO classified them and labeled them “epsilon” on May 31, 2021. These variants have a 20% higher efficiency than the original virus and can rapidly transmit from one individual to another.71 The researchers studied the neutralizing incidence of the epsilon variants on antibodies present in the plasma from COVID-19 recovered individuals and concluded that their potency was reduced.72 An estimated rise in the transmission rate is high and it is found in multiple other places in the United States.72

| Variant name | WHO label | Spike protein substitutions | Transmissibility | Immune evadesiveness | Vaccine effectiveness |
|--------------|-----------|-----------------------------|-----------------|---------------------|----------------------|
| B.1.1.7 Alpha | 31,39 69del,70del,144del, (E484K*),N501Y,A570D,D614G,P681H,T7161,S982A, D1118H (K1191N*) | ++ | + | + | _ | + | Yes | In the United Kingdom, September 2020 |
| B.1.351 Beta | D80A, D215G, 241del, 243del, K417N, E484K, N501Y, D614G, A701V | ++ | + | + | + | + | Yes | In South Africa, May 2021 |
| B.1.617.2 Delta | T19R, (G142D*), 156del,R158G,L452R,T478K,D614,E484K,N501Y,D614G,A701V | ++ | + | + | + | + | Yes | In India, April 2021 |
| P.1 Gamma | L18F, T20N,P26S,D138Y,R190S,K417T,E484K,N501Y,D614G,H655Y,T1027I | ++ | + | + | + | + | Yes | In Japan/Brazil, November 2020 |
| B.1.429 Epsilon | S13I,W152C,L452R,L452R,D614 | ++ | + | Yes | In California, USA, September 2020 |
| B.1.427 Epsilon | L452R, D614 | ++ | Yes | In California, USA, September 2020 |

Abbreviations: CDC, Centers for Disease Control and Prevention; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VOC, variant of concern; WHO, World Health Organization.

2.2.5 | Variants of concern

These emerging variants, B.1.1.7 and B.1.617.2 (epsilon variant), were designated as VOC 202012/01 by the WHO on June 1, 2021. The researchers studied the neutralizing efficacy of blood donors against these variants and concluded that their potency was reduced.72 The incidence of these variants in the United States is high and it is found in multiple other places in the United States.72
| Virus structure protein | SARS-CoV-2 genome site | Role | Mutation                                                                 | Alpha variant | Beta variant | Gamma variant | Epsilon variant | Delta variant | Omicron variant |
|-------------------------|------------------------|------|--------------------------------------------------------------------------|---------------|--------------|---------------|----------------|---------------|----------------|
| Spike protein           | ORF1ab                 | Binding protein regulation | PLpro: T183I PLpro: A890D PLpro: I14127 Nsp6: S106K RdRp: P323L nsp2: T85I PLpro: K837N | Yes           | No           | No            | No             | No            | No             |
|                         |                        |      | PLpro: K183R PLpro: S1265I PLpro: A1266 PLpro: A1892T nsp4: T492I 3CL: P132H nsp6: L105F nsp6: Δ106-108 nsp6: I189V RdRp: P323L nsp14: I42V PLpro: S370L PLpro: K977Q nsp6: S106K nsp6: Δ107-109 RdRp: P323L nsp13: E341D nsp4: V167L RdRp: P323L RdRp: G671S nsp13: P77L | No            | No           | No            | No             | No            | Yes            |
|                         |                        |      | No                                                                       | No            | No           | Yes           | No             | No            | No             |
|                         |                        |      | No                                                                       | No            | No           | No            | No             | Yes           | No             |

(Continues)
| Virus structure protein | SARS-CoV-2 genome site | Role | Mutation | Alpha variant | Beta variant | Gamma variant | Epsilon variant | Delta variant | Omicron variant |
|------------------------|------------------------|------|----------|---------------|-------------|---------------|----------------|---------------|----------------|
| **RBD**                |                        |      |          |               |             |               |                |               |                |
| RBD                    | Increase the binding affinity of the virus | | K417N | No | Yes | Yes | No | No | No |
|                        |                        |      | G339D    | No            | No          | No            | No             | No            | Yes            |
|                        |                        |      | S371L    |               |             |               |                |               |                |
|                        |                        |      | S373P    |               |             |               |                |               |                |
|                        |                        |      | S375F    |               |             |               |                |               |                |
|                        |                        |      | K417N    |               |             |               |                |               |                |
| **RBM**                |                        |      |          |               |             |               |                |               |                |
| RBM                    | Increase transmissibility and replication | | N501Y | Yes | Yes | Yes | No | No | No |
|                        |                        |      | E484K    | No            | Yes | Yes | No | No | No |
|                        |                        |      | L452R    | No | No | No | No | Yes | No |
|                        |                        |      | T478K    |               |             |               |                |               |                |
|                        |                        |      | N440K    | No | No | No | No | No | Yes |
|                        |                        |      | G446S    |               |             |               |                |               |                |
|                        |                        |      | S477N    |               |             |               |                |               |                |
|                        |                        |      | T478K    |               |             |               |                |               |                |
|                        |                        |      | E484A    |               |             |               |                |               |                |
|                        |                        |      | Q493R    |               |             |               |                |               |                |
|                        |                        |      | G496S    |               |             |               |                |               |                |
|                        |                        |      | Q498R    |               |             |               |                |               |                |
|                        |                        |      | N501Y    |               |             |               |                |               |                |
| **SD1**                |                        |      |          |               |             |               |                |               |                |
| SD1                    |                        |      | A570D    | Yes | No | No | No | No | No |
|                        |                        |      | Y505H    | No | No | No | No | No | Yes |
| **SD2**                |                        |      |          |               |             |               |                |               |                |
| SD2                    |                        |      | D614G    | Yes | Yes | No | No | No | No |
|                        |                        |      | H655Y    | No | No | Yes | No | No | No |
|                        |                        |      | D614G    | No | No | No | No | Yes | No |
|                        |                        |      | T547K    | No | No | No | No | Yes | No |
|                        |                        |      | D614G    |               |             |               |                |               |                |
|                        |                        |      | H655Y    |               |             |               |                |               |                |
| **S1/S2**              |                        |      |          |               |             |               |                |               |                |
| S1/S2                  |                        |      | P681H    | Yes | No | No | No | No | No |
|                        |                        |      | T7161    |               |             |               |                |               |                |
|                        |                        |      | A701V    | No | Yes | No | No | No | No |
|                        |                        |      | P681R    | No | No | No | No | Yes | No |
|                        |                        |      | D950N    |               |             |               |                |               |                |
|                        |                        |      | N679K    | No | No | No | No | No | Yes |
|                        |                        |      | P681H    |               |             |               |                |               |                |
|                        |                        |      | N764K    |               |             |               |                |               |                |
|                        |                        |      | D796Y    |               |             |               |                |               |                |
|                        |                        |      | N856K    |               |             |               |                |               |                |
|                        |                        |      | Q954H    |               |             |               |                |               |                |
| Virus structure protein | SARS-CoV-2 genome site | Role | Mutation | Variants of concern |
|------------------------|------------------------|------|----------|---------------------|
|                        |                        |      |          | Alpha variant | Beta variant | Gamma variant | Epsilon variant | Delta variant | Omicron variant |
| N                      |                        |      | N969K    | Yes           | No           | No           | No            | No           | No           |
|                        |                        |      | L981F715 |               |              |              |               |              |              |
|                        |                        |      | ORF8: Q27* | No           | Yes          | No           | No            | No           | No           |
|                        |                        |      | ORF8: R521 |               |              |              |               |              |              |
|                        |                        |      | ORF8: Y73C |               |              |              |               |              |              |
|                        |                        |      | N: D3L    |               |              |              |               |              |              |
|                        |                        |      | N: R203K  |               |              |              |               |              |              |
|                        |                        |      | N: G204R  |               |              |              |               |              |              |
|                        |                        |      | N: S235F  |               |              |              |               |              |              |
|                        |                        |      | ORF3a: Q57H | No           | No           | No           | No            | Yes          | No           |
|                        |                        |      | ORF3a: S171L |              |              |              |               |              |              |
|                        |                        |      | E: P71L   |               |              |              |               |              |              |
|                        |                        |      | N: T205I  |               |              |              |               |              |              |
|                        |                        |      | ORF3a: S26L | No           | No           | No           | No            | Yes          | No           |
|                        |                        |      | M: I82T   |               |              |              |               |              |              |
|                        |                        |      | ORF7a: V82A |              |              |              |               |              |              |
|                        |                        |      | ORF7a: T120I |             |              |              |               |              |              |
|                        |                        |      | ORF8: D119I |              |              |              |               |              |              |
|                        |                        |      | ORF8: Δ120-121 |             |              |              |               |              |              |
|                        |                        |      | N: D63G   |               |              |              |               |              |              |
|                        |                        |      | N: R203M  |               |              |              |               |              |              |
|                        |                        |      | N: D377Y  |               |              |              |               |              |              |
|                        |                        |      | E: T9I    |               |              |              |               |              |              |
|                        |                        |      | M: D3G    |               |              |              |               |              |              |
|                        |                        |      | M: Q19E   |               |              |              |               |              |              |
|                        |                        |      | M: A63T   |               |              |              |               |              |              |
|                        |                        |      | N: P13L   |               |              |              |               |              |              |
|                        |                        |      | N: Δ31-33 |               |              |              |               |              |              |
|                        |                        |      | N: R203K  |               |              |              |               |              |              |
|                        |                        |      | N: G204R  |               |              |              |               |              |              |
| Outside of spike protein| Enhanced transmissibility |     | Nsp6: Δ107-109 | Yes           | No           | No           | No            | No           | No           |
| NTD                    | Evasion of antibody neutralization |     | Δ69-70    | Yes           | No           | No           | No            | No           | No           |
|                        |                        |      | Δ144-145  |               |              |              |               |              |              |
|                        |                        |      | Δ69-70    |               |              |              |               |              |              |
|                        |                        |      | Δ69-70    |               |              |              |               |              |              |
|                        |                        |      | Δ69-70    |               |              |              |               |              |              |
|                        |                        |      | A67V      | No            | No           | No           | No            | No           | Yes          |
|                        |                        |      | Δ69-70    |               |              |              |               |              |              |
|                        |                        |      | T95I      |               |              |              |               |              |              |
|                        |                        |      | G142D     |               |              |              |               |              |              |

(Continues)
It has L452R mutation in S protein which was discovered in the RBD. It increases infectivity because of the interaction between spike protein and ACE2 receptors.75 W152C has been shown to diminish sensitivity to numerous NTD‐binding monoclonal antibodies, implying yet another involvement in immune evasion.76 Currently, it is considered a VOI. This variant demonstrated lower susceptibility to neutralization by convalescent (4–6.7‐fold) and postvaccination sera (2–2.9‐fold).58

2.2.5 | Delta variant

B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India’s second wave in this pandemic of COVID‐19. On May 31, 2021 WHO named this variant as "delta variant."77 Initially, the Delta variant was detected in India on May 7, 2021. Public health England (PHE) put the Delta variant in the category VOC from a variant under investigation (VUI). The spike protein mutations 19R, (G142D), 156del, 157del, R158G, L452R, T478K, D614G, P681R, and D950N identify and distinguish this variant. Several of these mutations, as well as the loss of a portion of the NTD, may affect immune responses aimed at the critical antigenic areas of RBD, that is, 452, 478, 156, and 157. The P681R mutation alters an amino acid right adjacent to the furin cleavage site, a crucial step, allowing the virus to penetrate human cells and thereby increasing viral infectivity.78 The spike protein of the new coronavirus is 1273 amino acids long. The RBD of the spike protein is perhaps the most important portion since it is crucial for connecting the SARS‐CoV‐2 virus toward the human ACE2 proteins on certain cells, allowing the virus to invade those cells.79 This variant is made up of a mutation in the gene that expresses the SARS‐CoV‐2 spike protein, which leads to substitutions in T478K, P681R, and L452R, that are designated to influence the infectiousness of the virus including its ability to be neutralized using antibodies against the formerly propagating form of COVID‐19 virus.80 Fragments 319–541 define the RBD. The receptor‐binding motif, which connects the spike protein to the human ACE2 receptor, is a critical governance motif in RBD. Any mutation that arises around amino acid residues 319–541—particularly between 438 and 506—may have a major influence on the infectivity of the virus, modes of transmission, intensity, and/or immunity‐evading capability.81 According to the PHE report, attacks of Delta variant were diagnosed more than 51%–67% than an Alpha variant.82 Another critical mutation in the RBD, L452R, increases cell transmission efficiency, allowing the variation to spread fast from one individual to another. This mutation is expected to permit 18%–24% increased transmissibility and a 20‐fold reduction in neutralizing titers from the vaccinated individual, as well as resistance to neutralization by particular antibodies.83 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19
convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment. Despite this, the B.1.617.1 variant was neutralized by the majority of sera from convalescent patients and all sera from vaccinated persons. The mRNA vaccines evaluated here are likely to protect against the B.1.617.1 mutation. Clinical data from vaccinated people should be used to better investigate this. In the UK experiment, the two-dose Pfizer vaccination was shown to be 87.9% effective against this variant (93.4% effective against B.1.1.7); the two-dose AstraZeneca vaccine was found to be 59.8% effective against this variant and 66.1% effective against B.1.1.7 (NCT04516746). Two weeks following the second treatment, Pfizer BioNTech and Oxford-AstraZeneca were 88% and 60% effective against the SARS-CoV-2 Delta strain, respectively. However, 3 weeks after the initial dose, both of these vaccinations are only 33% effective against the Delta form. The neutralization of the Pfizer-BioNTech and Moderna vaccines was reduced (Figure 3).

Delta plus variant (delta-AY.4.2)
As per records published to GISAID, the AY.4.2 lineage of COVID-19 is a subvariant of the Delta strain, has surfaced in six states of India, showing 17 instances documented yet. However, a team of specialists is still investigating this novel strain, which is considered to be responsible for the latest transmission surge in the United Kingdom. British officials have speculated that AY.4.2 might be significantly more communicable than Delta, albeit there is presently no proof that it triggered more extreme infections or rendered immunizations worthless. Two potential instances of the AY.4.2 strain were detected in India, and the items were transferred to a laboratory for genomic decoding. The alteration A1711V, which alters the virus’s NSP3 protein, and serves a variety of functions in viral replication, is the characterizing modification in AY.4.2. Nevertheless, the consequences of these changes are unclear.

2.2.6 | Omicron (C.1.2) variant

In November, Omicron was detected in Botswana. Many nations, particularly South Africa, have discovered a novel strain of COVID-19 known as C.1.2. On November 26, 2021, it was first found in India and later in many other countries. The current molecular tests detect most of the variants and thus are able to diagnose COVID-19 infection by such variants.
recognized as a VOC. Furthermore, instances of the novel variety have been recorded in Mauritius, England, Switzerland, New Zealand, Portugal, and the Democratic Republic of the Congo (DRC). According to some scientists, this new variant is more certain to be transferrable and can, to a certain degree, avoid the immunity established by vaccinations. Researchers discovered that this new C.1.2 variant is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant. Six of South Africa’s nine regions (along with the East and West Capes) had reported instances of C.1.2 strain as of August 13, 2021. Concerns are raised by a large number of spike mutations (at least 32 mutations). The variant is related to the lambda and beta variants, which are linked to innate immunity. K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant. According to preliminary laboratory findings, three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers. Omicron has a mutation known as N501Y, which allows the virus to attack to human cells more firmly. This mutation was found in the Alpha variant as well, and it was connected to its infectivity. According to computational modeling, the variant may also be immune to cell-mediated immune function. With the upsurge of Omicron VOC, countries must now definitely contemplate reinstating WHO-recommended fundamental healthcare and social disease standard precautions such as wearing well-fitting masks, hand hygiene, physical distance, improving indoor ventilation, and avoiding crowded areas if unimmunized. Nations must also speed up COVID-19 vaccination campaigns. According to the data, “the third dose of BNT162b2 increases neutralizing antibody titers by 25-fold when compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers seen after two doses against the wild-type virus, which are linked to high levels of protection. As the mutations in the Omicron form do not alter 80 percent of epitopes in the spike protein identified by CD8+ T cells, two doses may still protect against severe illness.” As per WHO, on 26 November, the WHO’s Technical Advisory Group on SARS-CoV-2 virus evolution declared PANGO lineage B.1.1.529 a VOC and designated it with the greek letter omicron. The heavily mutated Omicron coronavirus variant is likely to spread internationally and poses a very high risk of infection surges that could have severe consequences in some part of the globe (28 countries and Territories). Omicron has a great amount of formerly known mutations in other VOCs, involving at least 32 alterations in the spike protein alone compared with 16 mutations in the existing extremely contagious delta form, and several other viral replication proteins including in NSP12 and NSP14. The likely evolving pattern of the Omicron variation includes the possibility of circulation among chronically infected people. The emergence of the novel variation during the winter wave in various South African nations was undetected owing to poorer genome sequencing in some countries. Spike mutations may have improved Spike’s capacity to bind to the ACE2 receptor on host cells. Due to the huge number of mutations observed in the Omicron form, a secret animal reservoir might be responsible. The poor vaccination rate in Africa may have aided in the spread of the Omicron form. Omicron has a mutation known as N501Y, which allows the virus to attach to human cells more firmly. This mutation was found in the Alpha variant as well, and it was connected to its infectivity. According to computational modeling, the variant may also be immune to cell-mediated immune function. With the upsurge of Omicron VOC, countries must now definitely contemplate reinstating WHO-recommended fundamental healthcare and social disease standard precautions such as wearing well-fitting masks, hand hygiene, physical distance, improving indoor ventilation, and avoiding crowded areas if unimmunized. Nations must also speed up COVID-19 vaccination campaigns.

Convalescent sera from standard COVID-19 cohorts have performed poorly in neutralizing omicron. First, unlike Delta and other variations, Omicron prefers a cathepsin-dependent (E64d-sensitive) entrance path over a TMPRSS-like protease-dependent (Camostat-sensitive) entrance route. Such results may reflect the shift in viral tropism in host cells having varying levels of TMPRSS-like protease, and they point to a mixture of TMPRSS-like and cathepsin inhibitors as a safe therapy for all SARS-CoV-2 strains. Second, despite the P681H mutation, the fusogenicity of Mu and Omicron is much lower than that of other variations. Third, in accordance with fusogenicity, the proinflammatory action of Omicron S protein is mitigated. Fourth, the substantial mutations confer on Mu and Omicron variants the greatest capacity to evade immune protection from vaccination and mNAbs. Altogether, S protein mutations in Lambda, Mu, and Omicron variations change pathogenicity, fusogenicity, and immune function, posing a serious danger to current therapeutic and prophylactic techniques and emphasizing the significance of enforcing strong epidemic prevention measures. A research study conducted by Li et al. demonstrated that “molnupiravir and nirmatrelvir potently inhibited the infection of SARS-CoV-2 Omicron variant. The combination of molnupiravir and nirmatrelvir exerted synergistic antiviral activity.” Table 4 summarizes SARS-CoV-2 mutations of different VOCs.
2.3 | VOHC

It is proven that precautionary measures or medical countermeasures (MCMs) have remarkably lowered their effectivity in the case of VOHCs as compared with that of the abovementioned previously circulating variants.\(^2^6\) A piece of information to WHO under the international health regulations (IHR) is essential in case of these VOHCs, which is further, reported to CDC, which is an announcement to establish certain approaches to avert the transmission and guidance to update to solve this health crisis. Recently, SARS-CoV-2 variants showed infection to the degree of severity.\(^2^6\)

Due to COVID-19, the single most essential action required to manage the continuing SARS-CoV-2 epidemic is adequate vaccine administration. Even though numerous vaccines are being given under emergency use authorization, global immunization coverage will only be attained when vaccine supply surpasses vaccine demand.\(^2^8\) Governments and international private companies have invested billions of dollars in developing viable COVID-19 vaccines. More than 20 vaccines, including those from Pfizer and Moderna, BioNTech, and Sinopharm, have already been disseminated, with around half of the world's population having been properly immunized. Vaccines are subjected to extensive testing for safety and efficacy before they are licensed for use in the general population.\(^1^0^7\) Several prestigious institutes, universities, and major pharmaceutical corporations throughout the world have successfully generated COVID-19 vaccine candidates that have advanced to clinical trials. However, newly discovered variations may have an impact on their protective effects.\(^1^0^8\) Several reaction tactics have been proposed, including speeding major rollouts of existing vaccinations, enhancing vaccine immunogenicity through increased immunization doses, and accelerating next-generation vaccines against variations.\(^2^8,1^0^9\) In this crucial time, the world is preparing the most wide-reaching and most challenging immunization campaign and leveraging the vaccine's pharmaceutical production capabilities of delivering supplies of vaccines. Vaccination producers are now researching booster doses, which are additional doses of the same vaccine, as well as reformulated vaccinations to target particular variations.\(^1^1^0\) SARS-CoV-2 is constantly developing and mutating, giving birth to a variety of variations with varying degrees of infectivity and mortality.\(^1^1^1\) The virus, which first arose in China, mutated multiple times before causing havoc and taking countless lives globally as part of the continuing COVID-19 epidemic.\(^1^1^2\)

Following the Alpha, Beta, Gamma, and Delta variants, the most recently emerged VOC is the Omicron (B.1.1.529), which has evolved as a result of the accumulation of high numbers of mutations, particularly in the spike protein, raising concerns about its potential to dodge pre-existing immunity obtained through vaccination or infection, and also outperforming antibodies-based therapies.\(^1^1^3\) The Omicron is extremely transmissible and spreads quicker than any prior version; however, it may cause milder symptoms than earlier forms. The Omicron can evade immune system defenses, and coronavirus disease 2019 vaccinations are less effective against the Omicron version.\(^1^1^4\)

As of January 31, 2022, there have been more than 9.70 billion vaccine doses have been delivered globally, and over 46.7% global population is fully vaccinated. Despite differences in immunization efforts among countries, every effort is being taken to treat and prevent this virus.\(^1^1^5\)

3 | VARIANTS AND VACCINE EFFICACY

Since March 2020, we are facing a global pandemic because of COVID-19 and its different variants' mutation and this pandemic is having profound social and economic consequences globally. To tackle this hazardous condition, a vaccination strategy is found to be beneficial. In the manufacturing of COVID-19 vaccines, the focus was on its forms of molecular, particular, and cell-based types. All the vaccines fundamentally target to produce an antibody-mediated immune response.\(^1^1^6\) Efforts toward developing safe vaccines are taking place all across the world. Currently, approximately 149 vaccine approaches toward SARS-CoV-2 are being developed.\(^1^0^9\) At the time of writing, there are 168 vaccine candidates and 536 vaccine trials ongoing in more than 62 countries. There are 40 vaccines in phase I clinical trials, 58 in phase II trials, 62 in phase III trials, 33 approved vaccines, around 10 vaccine candidates are in phase IV post-licensure surveillance, and 8 vaccines that are not further progressing.\(^1^1^7,1^1^8\) The number of SARS-CoV-2 variations has increased as the virus has spread over the world.\(^1^1^9\) The implementation of long-term lockdowns to restrict the transmission of SARS-CoV-2 is not practicable owing to significant economic and social damage. As a result, worldwide public health measures, along with mass immunization, are the most viable way to contain the SARS-CoV-2 outbreak.\(^3\) A COVID-19 vaccine that is successful will very certainly involve both neutralizing antibodies and a T1-based cellular element. In this section, we analyze the influence of variant of concern on the immune responses generated with the four most commonly used vaccines, as well as their effectiveness.\(^1^2^0\) Pfizer, Moderna, BioNTech developed the m-RNA based vaccine while Covishield is an adenovirus vaccine.\(^1^2^1\) Russia invented the recombinant adenovirus vaccine Sputnik V and there were many other vaccines are also developed.\(^1^2^2\)

Furthermore, if some of the VOC have a higher risk of transmission or pathogenicity, the significance of effective public health interventions and immunization programs will grow.\(^7^2,1^2^3\) The international reaction must be both prompt and scientific. It is not hard to adapt vaccines to target mutations. Concerns have been raised concerning the ability to exist vaccinations to defend against new virus strains.\(^7^9,1^2^4\) S-glycoprotein mutations may influence transmission kinetics and the possibility of immunological escape.\(^1^2^5\) Vaccination decreases the incidence of delta variant infection and speeds up viral clearance, according to several studies.\(^1^1^9\) Despite this, fully vaccinated persons with breakthrough infections have peak viral loads comparable with unprotected patients and may easily spread illness in home settings, including completely vaccinated contacts.\(^1^2^6\) When an
| Vaccine platform                  | EUA vaccine candidate       | Company name                                      | % Efficacy of vaccine during Phase 3 trial | Effectiveness against variants |
|----------------------------------|-----------------------------|--------------------------------------------------|-------------------------------------------|-------------------------------|
| mRNA (Nucleic acid vaccine)      | Comirnaty (BNT162b2)        | Pfizer, and BioNTech                              | 95%                                      | Yes                           |
|                                  | Moderna COVID-19 vaccine (m-RNA-1273) | Moderna, BARDA, and NIAID                             | 94%                                      | No                            |
|                                  | Moderna spikevax            | Moderna                                           | 90%                                      | Yes                           |
| DNA (Nucleic acid vaccine)       | ZyCoV-D                     | Zydus Cadila                                      | 90%                                      | Yes                           |
| Nonreplicating viral vector vaccine | COVID-19 vaccine AstraZeneca (AZD1222); also known as Vaxzevria and Covishield | BARDA, OWS                                       | 76%                                      | Yes                           |
|                                  | Sputnik V                   | Gamaleya Research Institute, Acellena Contract Drug Research, and Development | 91%                                      | Yes                           |
|                                  | Sputnik light               | Gamaleya Research Institute, Acellena Contract Drug Research, and Development | 79.4%                                    | Yes                           |
|                                  | JNJ-78436735                | Janssen vaccines (Johnson & Johnson)               | 85%                                      | Yes                           |
|                                  | Convidicea                  | CanSino Biologics                                  | 65.7%                                    | Yes                           |
| Inactivated vaccine              | CoronaVac                   | Sinovac                                           | 51%                                      | Yes                           |
|                                  | BBIBP-CorV                  | Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | 78.1%                                    | No                            |
|                                  | Covaxin                     | Bharat Biotech                                    | 77.8%                                    | Yes                           |
|                                  | KoviVac                     | Chumakov Center                                   | 58%                                      | No                            |
|                                  | Turkovac                    | Health Institutes of Turkey                        | 60%                                      | No                            |
|                                  | KCONVAC                     | Minhai Biotechnology Co.                           | –                                        | No                            |
|                                  | FAKHRAVAC (MIVAC)           | Organization of Defensive Innovation and Research   | –                                        | Yes                           |
|                                  | QazVac                       | Research Institute for Biological Safety Problems (RIBSP) | 96%                                      | –                             |
|                                  | Inactivated (Vero Cells)     | Sinopharm (Wuhan)                                 | 79%                                      | –                             |
|                                  | COVIran Barekat              | Shifa Pharmed Industrial Co.                      | 93.5%                                    | –                             |
| Vaccine platform | EUA vaccine candidate | Company name | % Efficacy of vaccine during Phase 3 trial | Effectiveness against variants | Alpha variant | Beta variant | Gamma variant | Delta variant | Omicron variant |
|------------------|----------------------|--------------|-------------------------------------------|-------------------------------|---------------|-------------|--------------|--------------|----------------|
| Covilo           | Sinopharm (Beijing)  | 79%          | No                                        | No                            | No            | No          | Yes          | Yes          | No             |
| Protein subunit vaccine | EpiVacCorona | 79%          | No                                        | No                            | No            | No          | Yes          | No           | No             |
| SpikoGen         | Vaxine/CinnaGen Co.  | 60%          | Yes                                       | No                            | Yes           | No          | No           | No           | No             |
| Aurora-CoV       | Vector State Research Center of Virology and Biotechnology | 90%          | No                                        | No                            | No            | No          | No           | No           | No             |
| COVOVAX (Novavax formulation) | Serum Institute of India | 96.4%      | Yes                                       | No                            | –             | No          | No           | No           | No             |
| Razi Cov Pars    | Razi Vaccine and Serum Research Institute | 90%          | Yes                                       | No                            | Yes           | No          | Yes          | No           | No             |
| Recombinant SARS-CoV-2 Vaccine (CHO Cell) | National Vaccine and Serum Institute | –            | Yes                                       | No                            | Yes           | Yes         | No           | Yes          | No             |
| Nuvaxovid        | Novavax              | 92.6%        | Yes                                       | No                            | Yes           | No         | Yes          | Yes          | No             |
| MVC-COV1901      | Medigen              | –            | Yes                                       | No                            | –             | No         | Yes          | Yes          | No             |
| Soberana Plus    | Instituto Finlay de Vacunas Cuba | 91.2%      | –                                         | No                            | No            | Yes         | No           | No           | No             |
| Soberana 02      | Instituto Finlay de Vacunas Cuba | 92.4%      | –                                         | No                            | Yes           | No         | Yes          | No           | No             |
| Zifivax          | Anhui Zhifei Longcom | 82%          | –                                         | No                            | No            | Yes         | No           | No           | No             |
| Corbevax         | Biological E Limited | 90%          | No                                        | Yes                           | No            | Yes         | No           | No           | No             |
| Abdala           | Center for Genetic Engineering and Biotechnology (CIGB) | 92%          | No                                        | Yes                           | No            | Yes         | No           | No           | No             |

Abbreviations: EUA, Emergency Use Authorization; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
immunized group has concluded the main vaccination dose, booster doses are given when immunity in that community has dropped below a rate judged adequate over time. The goal of a booster dosage is to re-establish insufficient vaccination efficacy. Booster vaccination doses lowered both symptomatic and asymptomatic infection incidence similarly.\textsuperscript{1,2,4,46,127} Over 74% of global civilization has gotten one dose of the COVID-19 vaccine, and 54% is completely immunized against the disease. It has been provided in more than 6.70 billion doses across the world and 36.67 million doses are administered each day. Even in low-income nations, just 1.2% of the population has got at least one dosage of the drug.\textsuperscript{15,128} Table 5 provides brief information about the vaccine efficacy on the different variants of SARS-CoV-2. Some of these vaccines are currently in clinical testing, and their efficacy and effectiveness against various emerging viral variants are still being studied.\textsuperscript{139} And over 7.9% of COVID-19 vaccination programs have been delivered globally over a year of lockdowns and social isolation, and around 19.4% of people have been completely immunized.\textsuperscript{140} We, humans, are racing against time to develop immunity to this elusive virus, whose ability to mutate and evolve seems to be outpacing our ability to achieve herd immunity. Due to the new variants, it may be a sprint to the finish line.\textsuperscript{141}

We, humans, are racing against time to develop immunity to this elusive virus, whose ability to mutate and evolve seems to be outpacing our ability to achieve herd immunity. Due to the new variants, it may be a sprint to the finish line.\textsuperscript{142}

These variants are concerning for several reasons. First, the SARS-CoV-2 VOC spread at least 20%–50% more quickly from person to person. This encourages them to infect more people and grow faster and farther, gradually becoming the dominant paradigm. Second, SARS-CoV-2 VOC can create more acute illness, as well as an uptick in hospitalizations and deaths. In other words, they may be more virulent.\textsuperscript{143} According to Richard Lessells, “If a virus is going through an evolutionary process inside the host, then it is quite likely that it would be adapting to be better at entering the cells and evading the immune response; this could lead to a variant with enhanced transmissibility and enhanced immune evasion.”\textsuperscript{7}

Herbal remedies,\textsuperscript{144} drug repurposing, and nanotechnology-based formulations are also proved to be efficient in disease management.\textsuperscript{140–147} We can see the consequences: tragic deaths, worldwide epidemic outbreaks, and lockdowns.\textsuperscript{148} Research on vaccine efficacy, particular groundbreaking illnesses, and the capacity of postvaccination serum to destroy emerging variant viruses are major elements of assessing vaccination’s efficiency in managing COVID-19 in an arena of developing viral variants. Computational methodologies are used for the identification of SARS-CoV-2 specific mAbs and also to identify the suitability of existing mAbs for symptomatic management of COVID-19.\textsuperscript{149–152} Nasal administration of the nano based drug delivery will provide potential for the targeted delivery while in case of vaccine provide local immune protection.\textsuperscript{153–155} Finally, a concentrated and well-coordinated public health effort, as well as quick and broad adoption of effective vaccinations, is required to stay ahead of the inevitable emergence of variations that might severely expedite the pandemic’s progression.

4 | CONCLUSION

Generally, viruses mutate to adapt and sustain themselves in the environment. The critical thing here would be remembering this fact about COVID-19 as and when this situation is resolved. The need for instruments that enable quick identification and close monitoring of SARS-CoV-2 VOCs is higher than ever because these variants are more communicable and hence put more strain on health services. Non-Spike variants should be targeted for research into their involvement in escaping innate immunity and enhancing SARS-CoV-2 proliferation, as well as their relevance to viral viability more broadly. As viral variants have the ability to evade naturally acquired and vaccine-induced immunity, the invention of next-generation vaccines that trigger widely neutralizing action against present and possible future SARS-CoV-2 variants is the main objective. Control of transcription and replication by both public health interventions and fair vaccination dissemination is crucial in lowering the danger of novel variant creation. A validated immunization technique that is effective against the majority of VOCs is urgently needed. Scientists should consider nasal vaccination as well, as it delivers localized immunity. Furthermore, we should maintain extreme monitoring in following all preventative measures to limit the transmission of SARS-CoV-2.

AUTHOR CONTRIBUTIONS

Conceptualization: Vivek P. Chavda. Writing—original draft preparation: Aayushi B. Patel, Vivek P. Chavda, and Darsh D. Vaghasiya. Writing—review and editing: Vivek P. Chavda. All authors have read and agreed to the published version of the manuscript. Vivek P. Chavda, Darsh D. Vaghasiya, and Aayushi B. Patel dedicate this article to L.M. College of Pharmacy on the 75th Year celebration. Figure 1 is created with Biorender.com. For viral variant-related information, we have also referred to https://nextstrain.org/ and GISAID.

ACKNOWLEDGMENT

VP Chavda wants to dedicate this work to LM College of pharmacy as a part of the 75th year celebration of the college.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

ORCID

Vivek P. Chavda http://orcid.org/0000-0002-7701-8597
36. Choi JY, Smith DM. SARS-CoV-2 variants of concern. Yonsei Med J. 2021;62(11):961-968. doi:10.3349/ymj.2021.62.11.961
37. Rambaut A, Holmes EC, O’toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5(11):1403-1407. doi:10.1038/s41564-020-0770-5
38. Saxena SK, Kumar S, Ansari S, et al. Transmission dynamics and mutational prevalence of the novel severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern. J Med Virol. 2022;94:2160-2166. doi:10.1002/jmv.27611
39. Janga S, Ye C, Rathnasighe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe. 2021;2:283. doi:10.1016/S2666-5247(21)00068-9
40. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 vaccination on transmission of alpha and delta variants. BMJ. 2021;374:n3355. doi:10.1136/bmj.n3355
41. Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463-476. doi:10.1016/j.chom.2021.02.003
42. Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPapers [Internet]. StatPapers Publishing; 2022.
43. Burki T. The origin of SARS-CoV-2 variants of concern. Lancet Infect Dis. 2022;22(2):174-175. doi:10.1016/S1473-3099(22)00015-9
44. Division of Viral Diseases. SARS-CoV-2 Variant Classifications and Definitions. CDC Science, National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases; 2021. Access May 23, 2021. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
45. Domingo P, de Benito N. Alpha variant SARS-CoV-2 infection: how it all starts. EBioMedicine. 2021;74:74. doi:10.1016/j.ebiom.2021.103703
46. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal cohort study. Lancet Infect Dis. 2021;21:363. doi:10.1016/S1473-3099(21)00648-4
47. Roquebert B, Trombert-Baoukobza S, Haim-boukobza S, et al. The SARS-CoV-2 B.1.351 lineage (VOC B.1.351) is outgrowing the B 1. 1. 7 lineage in some French regions in April 2021. Euro Surveill. 2021;26(23):2100447.
48. Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270-274. doi:10.1038/s41586-021-03426-1
49. Hart WS, Miller E, Andrews NJ, et al. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. Lancet Infect Dis. 2022. doi:10.1016/S1473-3099(22)00001-9
50. Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 vaccination on transmission of alpha and delta variants. N Engl J Med. 2022;386(8):744-750. doi:10.1056/NEJMoa2116597
51. Duong D. Alpha, Beta, Delta, Gamma: what’s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;193(27):E1059-E1060. doi:10.1503/cmaj.1095949
52. Shen L, Bard JD, Triche TJ, Juzdiks AR, Biegel JA, Gai X. Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerg Microbes Infect. 2021;10(1):1293-1299. doi:10.1080/22221751.2021.1943540
53. Walker AS, Vihata K-D, Gethings O, et al. Tracking the emergence of SARS-CoV-2 alpha variant in the United Kingdom. N Engl J Med. 2021;385(27):2582-2585. doi:10.1056/NEJMct2103227
Otto SP, Day T, Arino J, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021;31(14):R918-R929. doi:10.1016/j.cub.2021.06.049

Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res. 2022;209:112816. doi:10.1016/j.envres.2022.112816

Gonzalez-Parra G. Analysis of delayed vaccination regimens: a mathematical modeling approach. Epidemiol. 2021;2(3):271-293. doi:10.3390/epidemiology2030021

Thiagarajan K. Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ. 2021;372:n196. doi:10.1136/bmj.n196

McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276-280.

Liu J, Liu Y, Xia H, et al. BNT162b2—Emergence of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276-280.

Edara V, Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and future challenges. J Infect Dis. 2022;214:268-272. doi:10.1016/j.jid.2021.11.040

Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276-280.

WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Accessed November 30, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

Petersen E, Ntoumi F, Hui DS, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)—highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268-272. doi:10.1016/j.ijid.2021.11.040

Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186-193. doi:10.1038/s41590-021-01122-w

Klemeš JJ, Jiang P, Fan YYan, Bokhari A, Wang X-C. COVID-19 pandemics Stage II—energy and environmental impacts of vaccination. Renew Sustain Energy Rev. 2021;150:111400. doi:10.1016/j.rser.2021.111400

Klemeš JJ, Jiang P, Fan YYan, Bokhari A, Wang X-C. COVID-19 pandemics Stage II—energy and environmental impacts of vaccination. Renew Sustain Energy Rev. 2021;150:111400. doi:10.1016/j.rser.2021.111400

Kosmitzki B, Glaser H, Tausch E, et al. Antibody activity of SARS-CoV-2 Spike protein E355C in the context of highly pathogenic Pneumovirus shedding: a new fusion function. BioRxiv. 2022;2021.06.04.20210597. doi:10.1101/2021.06.04.20210597

Chavda et al.
To KK, Sridhar S, Chiu KH, et al. Lessons learned 1 year after COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 2021;20(1):35. doi:10.1186/s12491-021-00438-7

Logette E, Lorin C, Favreau C, et al. A machine-learning-driven prediction of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. Infect Genet Evol. 2022;97:105164. doi:10.1016/j.meegid.2021.105164

Safabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021;34(3):1-63. doi:10.1128/CMR.00228-20

Vaccine G, Plan A. Global vaccine action plan. Vaccine. 2013;31:BS-B31. doi:10.1016/j.vaccine.2013.02.015

Singh R, Kang A, Luo X, et al. COVID-19: current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021;35(3):1-23. doi:10.1096/fj.202002662R

Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205-211. doi:10.1038/s41591-021-01230-y

WHO. COVID-19 Vaccine Tracker and Landscape, 2022. Accessed March 3, 2022. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Rees H, Roper AM, Sc B, et al. Special Report SARS-CoV-2 variants and vaccines, 2021:1-8.

Fiananag KL, Best E, Crawford NW, et al. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol. 2020;11(October):1-24. doi:10.3389/fimmu.2020.579250

Moore JP, Offit PA. SARS-CoV-2 Vaccines and the growing threat of viral variants. JAMA. 2021;325(9):821-822. doi:10.1001/jama.2021.1114

Loo KOY, Letchumanan V, Ser H-L, et al. COVID-19: insights into potential vaccines. Microorganisms. 2021;9(3):605. doi:10.3390/microorganisms9030605

Ren SY, Wang W-B, Gao R-D, Zhou A-M. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. 2022;10(1):1-11. doi:10.12998/wjcc.v10i1.1

Ciotti M, Ciccozzi M, Pieri M, Bernardini S. The COVID-19 pandemic: viral variants and vaccine efficacy. Crit Rev Clin Lab Sci. 2022;59(1):66-75. doi:10.1080/10408363.2021.1979462

Wald A. Booster vaccination to reduce SARS-CoV-2 transmission and infection. JAMA. 2022;327:327-328. doi:10.1001/jama.2021.23726

Rubin R. Sorting out whether vitamin D deficiency raises COVID-19 risk. JAMA. 2021;325(4):329-330. doi:10.1001/jama.2021.24127

Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for Omicron variant of SARS-CoV-2? Vaccines. 2022;10(3):367. doi:10.3390/vaccines10030367

Sallam M, Dababseh D, Eid H, et al. Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan. Int J Environ Res Public Health. 2021;18(5):2407. doi:10.3390/ijerph18052407

Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in healthcare workers, Israel. Euro Surveill. 2021;26(26):2100557. doi:10.2807/1560-7917.ES.2021.26.26.2100557

Coliffe S, Champion J, Moutrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2021;385(6):494-496. doi:10.1056/NEJMoa2119270

Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines. 2021;20(12):1549-1560. doi:10.1080/14760984.2021.1987223

Ikegame S, Siddiquy MNA, Hung C-T, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun. 2021;12(1):4598. doi:10.1038/s41467-021-24909-9

Sadowski J, Le Gars M, Shukarev G, et al. Interim results of a phase 1/2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. Published online January 2021;384:1824-1835. doi:10.1056/NEJMoas2034201

Duerr R, Dimartino D, Marier C, et al. Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. J Clin Invest. 2021;131(18):e152702. doi:10.1172/JCI152702

Doroffei B, Ciobica A, Ile O-D, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics. 2021;11(4):579. doi:10.3390/diagnostics11040579

Rao GSNK, Gowthami B, Naveen NR, Samudrala PK. An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Curr Res Pharmaco Stud. 2021;2:100063. doi:10.1016/j.crphs.2021.100063

Vacharathit V, Aiewsakun P, Manopwisedjarae S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021;21(10):1352-1354. doi:10.1016/S1473-3099(21)00568-5

Bharat Biotech. COVAXIN®—India’s First Indigenous COVID-19 Vaccine. Vol 154. 2021:1-6.

Shetty R, Ghosh A, Honavar SG, Khamar P, Sethu S. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future. Ind J Ophthalmol. 2020;68(5):693-702.

Chakraborty C, Sharma AR, Bhattacharya M, Agharamoorthi G, Lee S-S. Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis. Vaccines. 2021;9(6):600. doi:10.3390/vaccines9060600

Peacocke EF, Heupink LF, Frønsdal K, Dahl EH, Chola L. Global access to COVID-19 vaccines: a scooping review of factors that may influence equitable access for low and middle-income countries. BMJ Open. 2021;11(9):e049505-e049505. doi:10.1136/bmjopen-2021-049505

Veranda P. How worried should you be about coronavirus variants? A virologist explains his concerns. DownToEarth. April 9, 2021. Accessed March 2, 2022. https://www.downtoearth.org.in/blog/health/how-worried-should-you-be-about-coronavirus-variants-a-virologist-explains-his-concerns-76384

Eyawo O, Viens AM. Rethinking the central role of equity in the global governance of pandemic response. J Bioeth Inq. 2020;17(4):549-553. doi:10.1007/s11673-020-10001-2

Chavda VP, Patel AB, Vihol D, et al. Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update. Clin Complement Med Pharmacol. 2022;100021. doi:10.1016/j.ccmp.2022.100021

Chavda V, Sheta S, Changani D, Chavda D. New bioinformatics platform-based approach for drug design. In: Balamurugan S,
Krishnan A, Goyal D, Chandrasekaran B, Pandi B, eds. *Comput Bioinform*. Scrivener Publishing; 2021:101-120. doi:10.1002/9781119654803.ch6

146. Chavda VP, Chen R, Patel AB, Chen Z-S. Phytochemical delivery through Transferosome (Phytosome): an advanced transdermal drug delivery for complementary medicine. *Front Pharmacol*. 2022;13:850862.

147. Chavda VP. Nanotherapeutics and nanobiotechnology. In: Shyam M, Shivendu R, Nandita D, Raghvendra M, Sabu T, eds. *Applications of Targeted Nano Drugs and Delivery Systems*. Elsevier; 2019:1-13.

148. Nie J-B. In the shadow of biological warfare: conspiracy theories on the origins of COVID-19 and enhancing global governance of biosafety as a matter of urgency. *J Bioeth Inq*. 2020;17(4):567-574. doi:10.1007/s11673-020-10025-8

149. US FDA. Emergency Use Authorization (EUA) for etesevimab. fda.gov. 2021. Accessed February 22, 2022. https://www.fda.gov/media/145802/download

150. US FDA. Casirivimab with imdevimab—USFDA Factsheet. fda.gov. 2021. Accessed February 22, 2022. https://www.fda.gov/media/145612/download

151. Chavda V, Thalkari Y, Marwadi S. New strategies in drug discovery. *Comput Bioinform*. 2021;28:25-48. doi:10.1002/9781119654803.ch2

152. Chavda VP, Ertas YN, Walhekar V, et al. Advanced computational methodologies used in the discovery of new natural anticancer compounds. *Front Pharmacol*. 2021;12:702611.

153. Chavda VP. Chapter 4—nanobased nano drug delivery: a comprehensive review. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas SBT-A of TND and DS, eds. *Micro and Nano Technologies*. Elsevier; 2019:69-92.

154. Shah Dhaval, Chavda Vivek, Nasal HT. Medication conveyance framework: an approach for brain delivery from essential to cutting edge. *Res Rev J Med*. 2016;6(1):14-27.

155. Chen R-P, Chavda VP, Patel AB, Chen Z-S. Phytochemical delivery through transferosome (phytosome): an advanced transdermal drug delivery for complementary medicines. *Front Pharmacol*. 2022;13:850862.

How to cite this article: Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. *J Med Virol*. 2022;94:2986-3005. doi:10.1002/jmv.27717